AI Terminal
Zealand Pharma
Director's Dealing • Jan 13, 2025
3391_rpt_2025-01-13_36c7bf9d-0058-4a00-8176-c709dc33fbeb.html
Director's Dealing
Open in ViewerOpens in native device viewer
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 1 / 2025
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Copenhagen, Denmark, January 13, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.
Please see the attached file(s).
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contact:
Neshat Ahmadi
Investor Relations Manager
Email: [email protected]
Adam Lange
Investor Relations Officer
Email: [email protected]
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Email: [email protected]
Attachments
